Phanes Therapeutics has completed enrolment in its Phase II study of spevatamig in combination with standard-of-care che...
AnHorn Medicines has received U.S. FDA Investigational New Drug clearance and Taiwan Center for Drug Evaluation Index Ca...
Autoimmune and inflammatory diseases frequently affect the eye, yet ophthalmology has largely remained on the sidelines ...
The search for safer and more effective pain therapies remains one of medicine's most pressing challenges. Despite advan...
As artificial intelligence reshapes the future of genomic medicine, WhiteLab Genomics is positioning itself at t...
Artificial intelligence is rapidly transforming biologics discovery, but the industry's focus is shifting from generatin...
Despite decades of advances in oncology, many solid tumours remain difficult to treat effectively without exposing patie...
Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused o...
Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
As biologics and cell and gene therapies continue to advance, manufacturing infrastructure is emerging as a critical det...
As cell and gene therapies move from clinical promise to commercial reality, the industry is increasingly recognising th...
Cell and gene therapies have transformed the treatment landscape for complex diseases, yet scaling these innovations bey...
Researchers at the University of Otago, New Zealand are investigating a blood-based prostate cancer detection approach u...
Sonire Therapeutics has received approximately $13 million in non-dilutive funding through Japan’s NEDO Deep-Tech ...
South Korea-based LG AI Research has signed a master agreement with D&D Pharmatech for a joint next-generation oral ...
Niowave and Ratio Therapeutics have signed a supply agreement for Actinium-225, strengthening Ratio’s access to a ...
Hillhurst Bio has dosed the first subject in its Phase 2a clinical trial evaluating HBI-002 for the treatment of Parkins...
CARsgen Therapeutics has presented new clinical data for two allogeneic CAR-T cell therapy candidates, CT0596 and CT1190...
Rznomics has presented interim Phase 1/2a clinical data for RZ-001, its RNA editing-based anticancer gene therapy for re...
Inflammatory bowel disease is becoming a growing focus within immunology innovation across Asia-Pacific, as the region s...
MaaT Pharma has presented final Phase 3 data from the ARES pivotal trial evaluating MaaT013 in acute graft-versus-host d...
Pfizer has received US FDA approval for an expanded indication of Hympavzi for hemophilia A or B, broadening its use to ...
Eli Lilly has reported detailed Phase III results from three ACHIEVE trials evaluating Foundayo, or orforglipron, an ora...
VERTANICAL has received marketing authorisation in Germany for Exilby, or VER-01, for the treatment of chronic low back ...
The Department of Orthopaedic Surgery at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medi...
